NEW YORK (GenomeWeb) – Reponse Genetics said today that it has entered into a second amendment to a $12 million credit agreement. 

Separately, the company recently said that it has until June to comply with Nasdaq requirements in order for its stock to remain listed on the exchange. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.